|
 |
RisperidoneThis page contains recent news articles, when available, and an overview of Risperidone but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Risperidone (when available) Risperidone is an atypical antipsychotic medication. It is most often used to treat delusional psychosis (including schizophrenia), but Risperidone is also used to treat some forms of bipolar disorder and psychotic depression. It also has shown some success in treating symptoms of Asperger's Syndrome and autism. Risperidone is now the most commonly prescribed antipsychotic medication in the United States. For the treatment of schizophrenia Mechanism Of Action: Blockade of dopaminergic D2 receptors in the limbic system alleviates positive symptoms of schizophrenia such as hallucinations, delusions, and erratic behavior and speech. Blockade of serotonergic 5-HT2 receptors in the mesocortical tract, causes an excess of dopamine and an increase in dopamine transmission, resulting in an increase in dopamine transmission and an elimination of core negative symptoms. Dopamine receptors in the nigrostriatal pathway are not affected by risperidone and extrapyramidal effects are avoided. Like other 5-HT2 antagonists, risperidone also binds at alpha(1)-adrenergic receptors and, to a lesser extent, at histamine H1 and alpha(2)-adrenergic receptors. News Articles on Risperidone Held In A Psychiatric Ward and Called “Delusionalâ€? For Saying 9/11 ... - 30 Aug 2009 At night-time, I was forced to take Risperidone, a mind-altering medication administered to treat schizophrenia. I'd read about its dangerous side effects The People's Voice State Medicaid Cuts May Limit Market for New Antipsychotic Lurasidone - 30 Aug 2009 The recent availability of generic risperidone (Teva Pharmaceuticals, Mylan Inc) is contributing to this, as well. These factors reduce the potential market Gerson Lehrman Group Alkermes shares slip as J&J terminates 4-wk risperidone - Aug 27, 2009 N) have decided not to pursue further development of a four-week long-acting version of antipsychotic drug risperidone. Alkermes collects revenue for Reuters Zacks Analyst Blog Highlights: Alkermes, Inc., Johnson & Johnson ... - Aug 28, 2009 Risperidone, which is marketed as Risperdal Consta, is Alkermes' lead product. Risperdal Consta is the longer-lasting injectable version of Johnson Business Wire (press release) Markets Mixed As Economy Continues To Shrink - Aug 27, 2009 Johnson & Johnson (JNJ) ended its development of Alkermes' (NYSE: ALKS) month long version of its antipsychotic treatment risperidone. In the broad market, World Market Media STOCKS NEWS US-Goldman upgrades mid-cap brokers - Aug 27, 2009 Units of Johnson & Johnson have decided not to pursue further development of a four-week long-acting version of antipsychotic drug risperidone, Alkermes Inc Interactive Investor NEW YORK, Aug 27 (Reuters) - Some US stocks to watch on Thursday: - Aug 27, 2009 Units of Johnson & Johnson decided late Wednesday not to pursue further development of a four-week long-acting version of antipsychotic drug Risperidone. Forbes Saphris - New Drug Approved for Bipolar I Disorder - Aug 16, 2009 The reported side effects are comparable to those seen with other atypical antipsychotics such as risperidone and olanzapine. This means there will soon be About - News & Issues Evidence for the Partial Dopamine-Receptor Agonist Aripiprazole as ... - Aug 17, 2009 RESULTS: The search identified 17 studies, in which 3489 psychotic patients were given aripiprazole alone, as an adjuvant to haloperidol or risperidone, Psychosomatics (subscription) BRIEF-Alkermes: firms not pursuing risperidone - Aug 26, 2009 Interactive Investor Trading Limited, trading as "Interactive Investor", is authorised and regulated by the Financial Services Authority. Interactive Investor Dailly News: Study of Pharmacologic Treatments for Delirium ... - Aug 29, 2009 Multiple studies, however, suggest either shorter severity and duration, or prevention of delirium with the use of haloperidol, risperidone, gabapentin, Nurse.com Iloperidone Approved as “Second-Generationâ€? Benefits Debated - Aug 24, 2009 Rather than comparing the efficacy of iloperidone with risperidone and haloperidol, which had not previously favored iloperidone, the new trials compared Psychiatric Times Stocks on the move: Clean Energy, Conn's, NCI Building, Nyfix - Aug 27, 2009 ...and Janssen Pharmaceutica International decided not to pursue further development of the four-week long- acting injectable formulation of risperidone. San Mateo County Times Ask the Expert: Psychosomatic Medicine/Delirium - Aug 28, 2009 If an atypical antipsychotic is preferred, consider an agent with low sedation (ie, risperidone); unless a sedative agent is needed to restore the Focus (subscription) Guess: Analysts' Upgrades, Downgrades - Aug 27, 2009 JNJ is pulling away from the company's 4-week risperidone formulation. Alpha Natural Resources (ANR Quote) reinstated at Barclays with an Overweight rating TheStreet.com After-Hours Movers 8/26: JAS, GES Higher; ALKS, SIGM, CWTR Lower - Aug 26, 2009 ...that based on a portfolio review it has decided not to pursue further development of the four-week long-acting injectable formulation of risperidone. StreetInsider.com (subscription) NIMHANS gets Rs 30 lakh DBT funding for research on metabolic ... - Aug 28, 2009 ...of lipid and prolactin levels attributed to some anti psychotic drugs like olanzapine, clozapine, risperidone and other antipsychotics/psychotropics. pharmabiz.com Antidepressant Commonly Prescribed for Autism Found Utterly Useless - Aug 26, 2009 The only drug approved by the FDA to treat irritability and aggression in autistic children is the atypical antipsychotic risperidone. Natural News.com Upgrades & Downgrades: Barclays Gets a Boost - Aug 27, 2009 The price target also comes down to $11.50 from $14 after Johnson & Johnson (JNJ) pulled the plug on a four week formulation of risperidone. Minyanville.com FDA Panel OKs 3 Antipsychotic Drugs for Pediatric Use, Cautions ... - Aug 25, 2009 DB01124, DB00334, DB00246) Two atypical antipsychotic drugs, risperidone and aripiprazole, are currently approved for the treatment of these conditions in Journal of American Medical Association (subscription) Clozapine may have saved schizophrenics - Aug 24, 2009 ...haloperidol and risperidone increased the death risk by 41 percent, 37 percent and 34 percent respectively, when compared to older drugs. The Durango Herald Par Pharmaceutical Turns To Profit In Q2 - Update - Aug 4, 2009 ...tempered by an increase in volume of certain products such as tramadol APAP and fluoxetine HCl, as well as the launch of risperidone ODT in June 2009. RTT News Inside the DSM: The Drug Barons' Campaign to Make Us All Crazy - Aug 19, 2009 Journalist Evelyn Pringle has, more recently, reported on the CounterPunch website that Janssen-Cilag's antipsychotic Risperdal (chemical name, risperidone; CounterPunch Charles Bonnet syndrome: visual loss and hallucinations - Aug 3, 2009 A few case reports indicate that Charles Bonnet syndrome has been successfully treated with medications including risperidone, cisapride, valproate, CMAJ LiquidTycoon.com: TodayaEUR(TM)s Top NASDAQ Stock To watch ... - Aug 27, 2009 2009, that Units of Johnson & Johnson have decided not to pursue further development of a 4 week long-acting version of antipsychotic drug risperidone. Trading Markets (press release) Risperidone nella depressione maggiore non responsiva - Aug 29, 2009 Il risperidone sembra in grado di migliore i sintomi nella depressione maggiore non responsiva al trattamento standard. In questo studio multicentrico, Pillole.org Ontario demonstrates commitment to improve access to mental health ... - Aug 18, 2009 DRUGS OF TODAY,vol.43,no.4,pp.249-258,2007 (6) Cernansky J, Mahmoud R, Brenner R. A Comparison of risperidone and haloperidol for the prevention of relapse PharmaLive.com (press release) Corcept Therapeutics Announces Second Quarter 2009 Results and ... - Aug 11, 2009 The group of medications known as atypical antipsychotics, including olanzapine, risperidone, clozapine and quetiapine, are widely used to treat FOXBusiness Pipeline antipsychotic drugs will drive the next market evolution - Aug 7, 2009 Johnson & Johnson has successfully achieved differentiation with its depot formulation Risperdal Consta (risperidone), the first intramuscular injection, Trading Markets (press release) å…¨ç?ƒåŒ»è?¯å¸‚场：å?‘下的曲线 ç–²æ€?下å¥?å“?强音 - Aug 26, 2009 ...“弃儿â€?：å?¦æœ‰ä¸¤å?ªè?¯ç‰©è·Œå‡ºå??强å??å?•ã€‚2007å¹´ä½?居第七ä½?的强生è?¯ç‰©Risperdal（risperidone）和ä½?列第å??ä½?的安进è?¯ç‰©Arnasep（darbepoetin alfa）å?‡æœªå‡ºçŽ°åœ¨2008å¹´å‰?å??强 中国生物技术信息网 09:49 GAZZETTA UFFICIALE: SOMMARIO (2) - Aug 20, 2009 149) Modificazione dell'autorizzazione all'immissione in commercio, secondo procedura di mutuo riconoscimento, del medicinale "Risperidone Actavis" (Suppl. ANSA Valle d'Aosta 09:52 GAZZETTA UFFICIALE: SOMMARIO (2) - Aug 11, 2009 116 COMUNICATO Autorizzazione all'immissione in commercio del medicinale per uso umano "Risperidone AHCL" Pag. 117 COMUNICATO Autorizzazione all'immissione ANSA Valle d'Aosta Newer Antipsychotics May Lower Mortality in Schizophrenia - 14 Jul 2009 ...has not had a harmful effect on life expectancy of patients with schizophrenia, with the exception of quetiapine and risperidone," they said. MedPage Today Johnson & Johnson Reports 2009 Second-Quarter Results: - 14 Jul 2009 The FDA also approved the Supplemental New Drug Applications (sNDAs) for the use of RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Treatment as both PR Newswire (press release) 'í?´ë¡œìž?í•€' ì •ì‹ ë¶„ì—´ì¦? 사ë§?ë¥ ë‚®ì¶° - 14 Jul 2009 ...그밖ì—? 'í• ë¡œíŽ˜ë¦¬ë?Œ'(haloperidol)ì?´ 위험ì?„ 37%, '리스페달'(Risperdal, risperidone)ì?´ 34%, ìž?ì?´í”„ë ‰ì‚¬(Zyprexa, olanzapine)ê°€ 13% ë?”ìš± ì¦?가시켰다. 디지틀보사 Goedkoop medicijn het beste bij schizofrenie - 14 Jul 2009 Voor risperidone (Risperidal) is dat 35%. Ook bij olanzapine (bekende merknaam is Zyprexa dat vorige week nog negatief in het nieuws was vanwege de Blog.nl Injectable Risperidone Superior to Oral Quetiapine in Stable ... - Jul 1, 2009 All patients had been previously treated with oral risperidone, olanzapine, or oral conventional antipsychotics and needed a change in antipsychotic DG News Update on the safety of antipsychotic medicines - Jul 9, 2009 To date, just one antipsychotic medicine, risperidone has been authorised in Ireland for short-term (up to 6 weeks) treatment of persistent aggression in Irish Medical Times Persistent Psychosis Associated With Salvia Divinorum Use - Jul 1, 2009 He attempted to barricade himself in his room. Risperidone (3 mg by mouth/three times per day) was administered, and the patient was eventually stabilized. Am J Psychiatry (subscription) Valacyclovir-Induced Psychosis and Manic Symptoms in an Adolescent ... - Jun 30, 2009 Valacyclovir treatment was stopped, and risperidone was initiated. RESULTS: The symptoms continued after stopping the valacyclovir, but improved with Psychosomatics (subscription) Antipsychotic drug use spiralling in kids, research says - Jul 2, 2009 ..."None of the atypical antipsychotics approved in Canada [Risperidone, Quetiapine, Olanzapine, Clozapine, Paliperidone, Ziprasidone] are indicated for use in CBC.ca Seroquel's First- and Second-Line Patient Share Has Grown Since ... - Jun 22, 2009 The new report entitled Treatment Algorithms in Bipolar Disorder also finds that although risperidone is now available in generics there is no clear PR Newswire (press release) The anti-psychotic drugs in your kids' pockets - Jul 2, 2009 Risperidone, sold under the trade name Risperdal in the United States and Canada, changes the effects of chemicals in the brain, and is used to treat Global HSE 'could save millions on drugs' - Jul 13, 2009 ...at a fraction of the current cost include Lansoprazole, Pravastatin, Pantoprazole, Amlodipine, Alendronic acid, Venlafaxine, Doxazosin and Risperidone. Irish Health Scoop Essentials: The Good Doc Is In - Jun 23, 2009 Risperidone/Risperidal, while occasionally helpful in decreasing anxiety, is more often used in autism for aggressiveness and agitation. Disability Scoop The Effect of Antipsychotics on the High-Affinity State of D 2 and ... - Jul 6, 2009 Objectives To examine the effects of antipsychotics (clozapine, risperidone, or olanzapine) on the high- vs high- + low-affinity sites of the D 2 and D 3 Archives of General Psychiatry FDA Advisors Back Additional Antipsychotics for Use in Teens - Jul 3, 2009 Two other second-generation antipsychotics (SGAs), risperidone and aripiprazole, have previously been approved for treating schizophrenia in patients aged Psychiatric News BioLineRx Announces New Results Confirming the Mode of Action of ... - Jun 20, 2009 ...patients were randomized to one of four arms, receiving a low dose or high dose of BL-1020; risperidone, an approved atypical schizophrenia drug; MarketWatch Citalopram Ineffective As Drug For Autism, Causing Significant ... - Jun 30, 2009 ...“Well-done studies, using methods like the ones in this study, have shown that another drug, risperidone, is useful in reducing irritability and aggression EmpowHer Brief Intervention for Anxiety in Primary Care Patients - Jun 18, 2009 Placebo-controlled trial of risperidone augmentation for selective serotonin reuptake inhibitor-resistant civilian posttraumatic stress disorder. Medscape But how might Demerol/meperidine have caused cardiac arrest, the ... - Jun 26, 2009 ...pramipexole; pregabalin [7523], quetiapine; risperidone; ropinirole; skeletal muscle relaxants; trimipramine; tolcapone; tramadol [5043]; and trazodone. ScienceBlogs Bipolar Illness and Tardive Dyskinesia - Jun 22, 2009 I've tried taking some of the newer meds such as Risperidone, Quetiapine Fumarate, and Olanzapine, but none of them worked for me. EmpowHer Concern by media on antipsychotic treatment by general practitioners - Jun 24, 2009 In all cases but one, the antipsychotic started by the consultant psychiatrist was the newer atypical antipsychotic risperidoneâ€?, pointing out however that Malta Independent Online Drug panel: call to axe 2 health experts - Jun 21, 2009 The delay in establishing a national drug system development committee has affected public access to essential drugs such as Risperidone and Setraline, Nation Multimedia 얀센, ì •ì‹ ë¶„ì—´ì¹˜ë£Œ 'ì?¸ë² ê°€' ì‹œíŒ? - Jun 28, 2009 ...ì?¸ë² ê°€ì?˜ 성분명ì?€ 팔리페리ë?ˆ(Paliperidone)으로, í• ë¡œíŽ˜ë¦¬ë?Œ(Haloperidol), 리스페리ë?ˆ(Risperidone)ì—? ì?´ì–´ í•œêµì–€ì„¼ì?´ êµë‚´ì—? ì‹œíŒ?하는 세 번째 í•ì •ì‹ 병 ì•½ì œ 디지틀보사 Malattia di Alzheimer: l'impiego degli antipsicotici nel ... - Jul 2, 2009 Giovedì 2 Luglio 2009 - In Gran Bretagna solo un farmaco antipsicotico, Risperidone ( Risperdal ) è autorizzato nel trattamento dei disturbi comportamentali XagenaSalute Schizofrenia: i farmaci antipsicotici di seconda generazione non ... - Jul 13, 2009 Deniban ] -0,31 p<0.0001; Clozapina [ Clozaril ] -0,52 p<0.0001, Olanzapina [ Zyprexa ] -0,28, p<0.0001 e Risperidone [ Risperadl ] -0,13 p=0.002 ). XagenaSalute Les troubles du spectre autistique : de la science à l'obscurantisme - Jul 13, 2009 Malgré cela, la risperidone est responsable d'une importante prise de poids, de sédation et d'un risque métabolique (DGAS, 2007, p252). AgoraVox Gli antipsicotici in gravidanza sono rischiosi? - Jun 30, 2009 ...flupentixolo, flufenazina) e gli antipsicotici di seconda generazione (come clozapina, risperidone, olanzapina, quetiapina, ziprasidone, aripiprazolo, Associazione Italiana Psichiatri Brand Names/Synonyms: Risperidone is also known by the following brand names and/or synonymsCHEMBANK1795; R118; Remeron; Risperdal; Risperdal Consta; Risperdal M-Tab; Risperidal M-Tab; Risperidona [Spanish]; Risperidone; Risperidone [Usan:Ban:Inn]; Risperidonum [Latin]; Risperin; Rispolept; Rispolin; Sequinan Drug Category: Risperidone is categorized under the following by the FDA: Antipsychotics; Antipsychotics; ATC:N05AX08 Dosage Forms: Tablets and oral solution Absorption: Risperidone is well absorbed. The absolute oral bioavailability of risperidone is 70% (CV=25%). The relative oral bioavailability of risperidone from a tablet is 94% (CV=10%) when compared to a solution. Pharmacokinetic studies showed that RISPERDAL® M-TAB™ Orally Disintegrating Tablets and RISPERDAL® Oral Solution are bioequivalent to RISPERDAL® Tablets Interactions: -->Interactions for Risperidone: The interactions of RISPERDAL® and other drugs have not been systematically evaluated. Given the primary CNS effects of risperidone, caution should be used when RISPERDAL® is taken in combination with other centrally acting drugs and alcohol. Because of its potential for inducing hypotension, RISPERDAL® may enhance the hypotensive effects of other therapeutic agents with this potential. RISPERDAL® may antagonize the effects of levodopa and dopamine agonists. Amytriptyline does not affect the pharmacokinetics of risperidone or the active antipsychotic fraction. Cimetidine and ranitidine increased the bioavailability of risperidone, but only marginally increased the plasma concentration of the active antipsychotic fraction. Chronic administration of clozapine with risperidone may decrease the clearance of risperidone. Carbamazepine and Other Enzyme Inducers In a drug interaction study in schizophrenic patients, 11 subjects received risperidone titrated to 6 mg/day for 3 weeks, followed by concurrent administration of carbamazepine for an additional 3 weeks. During co-administration, the plasma concentrations of risperidone and its pharmacologically active metabolite, 9-hydroxyrisperidone, were decreased by about 50%. Plasma concentrations of carbamazepine did not appear to be affected. The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy. Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment. Fluoxetine and Paroxetine Fluoxetine (20 mg QD) and paroxetine (20 mg QD) have been shown to increase the plasma concentration of risperidone 2.5-2.8 fold and 3-9 fold respectively. Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone. Paroxetine lowered the concentration of 9-hydroxyrisperidone an average of 13%. When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of RISPERDAL®. The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied. Lithium Repeated oral doses of risperidone (3 mg BID) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (n=13). Valproate Repeated oral doses of risperidone (4 mg QD) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (n=21). However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone. Digoxin RISPERDAL® (0.25 mg BID) did not show a clinically relevant effect on the pharmacokinetics of digoxin. Drugs That Inhibit CYP 2D6 and Other CYPIsozymes Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs. Drug interactions that reduce the metabolism of risperidone to 9-hydroxyrisperidone would increase the plasma concentrations of risperidone and lower the concentrations of 9-hydroxyrisperidone. Analysis of clinical studies involving a modest number of poor metabolizers (n 70) does not suggest that poor and extensive metabolizers have different rates of adverse effects. No comparison of effectiveness in the two groups has been made. In vitro studies showed that drugs metabolized by other CYPisozymes, including 1A1, 1A2, 2C9, 2C19, and 3A4, are only weak inhibitors of risperidone metabolism. There were no significant interactions between risperidone and erythromycin. Drugs Metabolized by CYP 2D6 In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6. Therefore, RISPERDAL® is not expected to substantially inhibit the clearance of drugs that are metabolized by this enzymatic pathway. In drug interaction studies, risperidone did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP 2D6. |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |